Board summary
Key figures
45,823
Registered population
61.0% aged 18–64
18.0%
Aged 65+
ICB 18.8% · England 17.9%
13.5%
Ethnic minority (non-White)
7.1% Asian · England 9.6%
0.0%
In IMD quintile 1
ICB 0.8% · England 21.0%
0
Core20 residents (est.)
Resident basis; registered basis 0 · see page 3
6,547
Hypertension register
+3.44% in 3 yrs · England +5.60%
398
SMI register
54.7% of Runnymede's
712
COPD register
Reviews -8.99% in 3 yrs
Forecast to 2030
7,871
Hypertension patients, 2016
+1,324 on today
62.9%
QRISK ≥20% on statins, 2016
+0.15pp over 3 yrs
5.0%
Cancer prevalence, 2016
England 4.5%
Three things the board should see
Respiratory annual reviews lag behind local benchmarks.
COPD reviews fell 9.0% over 2023 to 2025 (England +2.8%), and asthma reviews at 65.5% (Runnymede 71.0%) leave about 866 of 2,509 patients unreviewed.
Older-adult blood pressure and statin uptake trail England.
QRISK ≥ 20% lipid therapy reached 62.6% (+0.2% vs England +6.2%) while 80+ BP control fell 1.5% to 78.9%, alongside £29,387 higher lipid-modifying spend.
Non-frail diabetes and under-80 blood pressure control improved.
Non-frail diabetes HbA1c control grew +10.2% to 59.1% (England 57.4%, +4.4%) and under-80 hypertension BP control rose +7.1% to 69.1% (England 67.8%, +3.2%).
Population, age and ethnicity
Registered list reaches 45,823 with 21.0% aged under 18 and 9.1% projected growth
COCO PCN has 45,823 registered patients across member practices. Children aged 0–17 comprise 21.0% of the list (9,631 patients), above Runnymede (19.7%), NHS Surrey Heartlands ICB (20.4%), and England (19.6%). Adults aged 65+ represent 18.0% (8,237 patients; Runnymede 17.9%, ICB 18.8%, England 17.9%). Unverified projections indicate 9.1% list growth by 2030 (Runnymede 9.8%, ICB 4.9%, England 2.3%). Area Census residents show 86.5% White (Runnymede 83.5%, ICB 85.3%, England 81.1%) and 13.5% ethnic minority residents (Asian 7.1%), reflecting resident rather than registered ethnicity.
Age profile
65+: ICB 18.8%, England 17.9%
Ethnicity
Older people · falls rows are Runnymede local-authority (LA) data, not PCN
| Measure | Local | South East | England | Period |
|---|---|---|---|---|
| Falls admissions, 65+, per 100,000 (Runnymede LA) | 1,771 | 2,018 | 1,958 | 2024/25 |
| Diabetes with frailty: HbA1c ≤75 mmol/mol (PCN) | 86.5% | 82.2% | 81.9% | 2024/25 |
| Diabetes without frailty: HbA1c ≤58 mmol/mol (PCN) | 59.1% | 57.8% | 57.4% | 2024/25 |
| Falls admissions, 65 to 79, per 100,000 (Runnymede LA) | 829 | 981 | 955 | 2024/25 |
| Falls deaths, all ages, per 100,000 (Runnymede LA) | 11.6 | 14.0 | 14.8 | 2022‑24 |
Deprivation and Core20
The PCN records 0.0% Core20 share despite an average IMD decile of 6.7
COCO PCN records a 0.0% Core20 share, below Runnymede (1.4%), NHS Surrey Heartlands Integrated Care Board (0.8%), and England (21.0%), giving 0 estimated Core20 residents. Its average IMD decile of 6.7 is below Runnymede (7.3) and the ICB (7.9), but above England (5.5). The PCN also holds 54.7% of Runnymede's severe mental illness register (398 patients) and 59.1% of its learning disability register (233 patients). Zero area-level deprivation may mask household need, suggesting outreach should focus on clinical registers rather than geographic deprivation.
% of patients in IMD quintile 1, by practice
Dashed line: England 21.0% · right column: Core20 patients, registered basis
PLUS groups and inclusion health
PLUS groups and inclusion health
398
SMI register
0.88% recorded prevalence
233
Learning disability register
0.51% recorded prevalence
11
Care homes, 514 beds
In the PCN catchment
8.2%
Provide unpaid care
Runnymede, Census 2021
The PCN records 398 severe mental illness patients (0.9% vs England 1.0%) and 233 with learning disabilities (0.5% vs England 0.6%), representing 54.7% and 59.1% of Runnymede's caseloads, alongside 11 catchment care homes (514 beds). Runnymede records 8.2% unpaid care and 7 rough sleepers separately. Carrying over half the borough's inclusion-health caseload despite register prevalence below England makes protecting annual physical-health check capacity the operational priority.
Severe mental illness: physical health checks
SMI blood pressure checks reached 88.6% (+0.03 pp over three years vs England +4.4 pp) and BMI recording reached 88.9% (+0.6 pp vs +5.1 pp). While both exceed England (83.4% and 82.1%), three-year progress has slowed.
Clinical focus: hypertension and lipids
Clinical focus: hypertension and lipids
6,547
Hypertension register
+3.44%
Register growth, 3 yrs
Runnymede +4.39% · England +5.60%
+4.61pp
BP control, under 80
≤140/90 · −1.23pp aged 80+
+1,324
More patients by 2030
Forecast 7,871 (15.46%)
Hypertension case-finding and control
Hypertension prevalence is 14.4% (6,547 patients), in line with Runnymede (14.1%) and NHS Surrey Heartlands Integrated Care Board (14.3%), and below England (15.2%). Blood pressure control in patients aged under 80 reached 69.1%, rising +7.1% over three years (England +3.2%). Conversely, blood pressure control for patients aged 80 and over fell 1.5% over three years to 78.9%, trailing Runnymede (79.6%, +1.4%), the ICB (79.9%, +1.7%), and England (81.2%, +2.2%). Control for patients aged 80 and over was 72.5% at Crouch Oak Family Practice and 82.9% at Chertsey Health Centre. Declining blood pressure control in patients aged 80 and over indicates a need to review management protocols in older cohorts.
Lipids and statins
Lipid-lowering therapy for patients with QRISK ≥ 20% is 62.6%, exceeding Runnymede (61.8%) and the ICB (59.4%) but trailing England (63.6%). Over three years, treatment grew +0.2% locally against +6.2% nationally. Statin treatment uptake in high-risk patients lags national growth.
| Measure | Items | Cost / item | ICB | England | Annual spend |
|---|---|---|---|---|---|
| Lipid-modifying, 2026 | 54,421 | £2.40 | £2.24 | £1.86 | £130,610 |
| Cardiovascular (all), 2025 | 84,557 | £4.79 | £4.74 | £3.33 | £405,028 |
For lipid-modifying drugs in 2026, the PCN prescribed 54,421 items at £2.40 per item, compared with £2.12 in Runnymede, £2.24 in the ICB, and £1.86 in England. The PCN spent £29,387 more than at England's unit cost across these items. Higher unit cost per item may reflect local formulary choices across prescribed agents.
Clinical focus: respiratory, cancer register and children
Clinical focus: respiratory, cancer register and children
Respiratory
−0.32%
Asthma reviews, PCN 3-yr % change
+4.44%
Asthma reviews, England 3-yr % change
+3.79%
Asthma prevalence, PCN 3-yr % change
COPD annual reviews fell 9.0% over three years to 77.2% (Runnymede 81.4%, England +2.8%), reaching 70.7% at Crouch Oak Family Practice and 85.2% at New Ottershaw Surgery. Asthma reviews reached 65.5% (falling 0.3% vs England +4.4%), trailing Runnymede (71.0%) and leaving an estimated 866 of 2,509 register patients unreviewed. COPD prevalence is 1.6% (712 patients). Declining review trends indicate delivery lags for diagnosed respiratory patients.
Cancer register and children's immunisation
Cancer prevalence is 4.1% (1,848 patients; England 3.8%). Childhood 6-in-1 coverage at 12 months reaches 96.0% (England 91.0%). By age 5, MMR dose 2 drops to 88.5%, trailing dose 1 (93.8%) by 5.3 pp, and 4-in-1 booster coverage falls to 85.4%, below the 95.0% target by 9.6 pp. Preschool booster drop-off leaves older children under-protected despite strong infant uptake.
Dashed line: 95% national coverage target · solid tick: England
Early cancer diagnosis
Early cancer diagnosis
61.4%
Surrey Heartlands ICB, stage 1–2
55.3%
England, 2022
75%
National ambition by 2028
~650
Extra early-stage cases a year to reach the ambition
| Stage 1–2 share by cancer type, 2022 | Surrey Heartlands ICB | England | No usable stage | Staged cancers |
|---|---|---|---|---|
| Prostate | 65.7% | 53.2% | 18% | 1,044 |
| Breast | 88.2% | 85.4% | 27% | 798 |
| Bowel | 48.1% | 47.0% | 18% | 626 |
| Lung | 33.2% | 33.8% | 17% | 497 |
| Skin cancer | 89.8% | 87.8% | 19% | 384 |
In 2022, 61.4% of cancers with a known stage in NHS Surrey Heartlands ICB were diagnosed at stage 1 or 2 (England 55.3%), 13.6 percentage points below the 75.0% national ambition. This gap represents approximately 652.5 additional early-stage cases across 4,810 staged cancers (67.7% known-stage coverage out of 7,106 registered cancers). Early detection was 88.2% in breast and 65.7% in prostate, but lower in bowel (48.1%) and lung (33.2%). Meanwhile, PCN breast screening coverage reached 66.0%, trailing England (69.9%) and the ICB (71.2%). Stage data reflects ICB system delivery rather than PCN performance, but lower screening uptake may constrain early identification.
Cancer waits, diagnostics and community services
Cancer waits, diagnostics and community services
Cancer waits and diagnostics, Jul 2026 (provisional)
In July 2026, Ashford and St Peter's Hospitals NHS Foundation Trust achieved 85.5% on the 28-day faster diagnosis standard (exceeding the 75.0% target), but reached 76.4% on the 62-day treatment standard, 8.6 percentage points below the 85.0% standard. Comparatively, Kingston and Richmond NHS Foundation Trust achieved 75.3% and Frimley Health NHS Foundation Trust 81.8%, against 71.5% across NHS Surrey and Sussex Integrated Care Board and 71.2% in England. Ashford and St Peter's diagnostic 6-week waits matched England at 23.1%, but endoscopy faced pressure, including colonoscopy at 49.6% and gastroscopy at 56.7%, which could delay gastrointestinal investigation pathways.
| Pathways within standard (%) | Ashford and St Peter's | Frimley Health | Kingston and Richmond | Surrey and Sussex ICB | England |
|---|---|---|---|---|---|
| 28-day faster diagnosis (75%) | 85.53 | 87.95 | 80.07 | 79.29 | 79.32 |
| 31-day treatment (96%) | 94.21 | 92.89 | 98.77 | 90.45 | 92.50 |
| 62-day referral to treatment (85%) | 76.38 | 81.84 | 75.32 | 71.51 | 71.16 |
| Diagnostic waits over 6 weeks (%) | Ashford and St Peter's | Frimley Health | Kingston and Richmond | England |
|---|---|---|---|---|
| MRI | 0.09 | 12.85 | 0.19 | 21.40 |
| CT | 9.27 | 0.63 | 0.00 | 9.92 |
| Echocardiography | 0.97 | 3.35 | 4.89 | 28.48 |
| Colonoscopy | 49.61 | 22.84 | 70.17 | 30.83 |
| Gastroscopy | 56.74 | 7.43 | 79.18 | 29.02 |
| All 15 DM01 tests | 23.12 | 7.49 | 31.56 | 23.14 |
| Community services activity | Surrey residents | Surrey and Sussex ICB |
|---|---|---|
| Care contacts | 109,530 | 309,615 |
| Referrals | 28,700 | 66,930 |
| Patients with a contact | 33,510 | 85,660 |
Community services (residents of Surrey), Jun 2026 (provisional). In June 2026, provisional community services data recorded 109,530 care contacts and 66,060 care activities for Surrey residents, with NHS Surrey and Sussex Integrated Care Board reporting 309,615 contacts overall. Adults aged 65 and over accounted for 69.6% of Surrey resident contacts (76,215 contacts). These experimental figures reflect broad upper-tier activity and submitting providers rather than distinct COCO PCN patient cohorts.
Practice variation and patient experience
Phone access varies by 28.2 pp and QOF vaccination achievement spans 16.4 pp
Overall QOF achievement reached 95.8% at Crouch Oak Family Practice, 95.3% at New Ottershaw Surgery, and 91.5% at Chertsey Health Centre (England 92.5%). Vaccination and immunisation achievement spanned a 16.4 pp range, from 46.7% at Chertsey Health Centre to 63.0% at Crouch Oak Family Practice (England 55.2%), indicating marked variation in preventive delivery across member practices.
GP Patient Survey by practice
| Practice | Responses | % in IMD Q1 | Phone easy | Request led to appt | Overall good |
|---|---|---|---|---|---|
| New Ottershaw | 105 | 0.0 | 83.2% | 84.5% | 94.7% |
| Crouch Oak | 112 | 0.0 | 54.9% | 69.5% | 82.0% |
| Chertsey | 92 | 0.0 | 63.6% | 70.5% | 78.7% |
| England | — | ~21 | 56.9% | 71.6% | 76.7% |
Where the PCN lags
Fifteen of 25 compared measures trailed England's three-year change, led by chronic disease reviews
Fifteen of 25 compared measures trailed England's three-year change. The widest relative lags were in annual chronic disease reviews: heart failure fell 3.1% (England +8.7%) and COPD fell 9.0% (England +2.8%). Alcohol recording in psychosis fell 1.0 pp (England +5.4 pp), while QRISK 20% or over statin therapy rose 0.2% (England +6.2%). Conversely, key clinical control indicators outperformed national progress: non-frail diabetes HbA1c control rose 10.2% (England +4.4%), under-80 hypertension control rose 7.1% (England +3.2%), and hypertension treated to target rose 5.3% (England +3.6%).
3-year change · PCN vs England
Bars show the direction and scale of relative change. Orange: PCN · Grey: England.
Heart failure reviews
COPD reviews
Alcohol record (psychosis)
QRISK statin treatment
Asthma reviews
Diabetes HbA1c control
BP control, under 80
Hypertension treated to target
What the data can't tell us: gaps and local assets
What the data can't tell us: gaps and local assets
| Local assets and voluntary sector | PCN | Runnymede | Asset | PCN | Runnymede |
|---|---|---|---|---|---|
| Care homes (catchment) | 11 (514 beds) | n/a | Schools (catchment) | 44 | n/a |
| Children's centres | 3 | 5 | Places of worship | 16 | 38 |
| Libraries | 3 | 6 | Homelessness support (VCS) | 0 | no data |
| Day centres (VCS) | 1 | 1 | Carers support groups (VCS) | n/a | 1 |
| Primary schools (LA maintained) | 6 | 10 | Primary academies | 6 | 7 |
0 = the source returned zero. n/a = not held at this level. No data = no value returned; this does not mean zero.
Options for the PCN
Options for the PCN
Each option in full
Option 1
Structured respiratory annual review recall
Asthma reviews reached 65.5% (Runnymede 71.0%, England 65.7%; -0.3% vs England +4.4% over three years), leaving 866 of 2,509 patients unreviewed; COPD reviews fell 9.0% to 77.2% across 712 patients (Runnymede 81.4%, England +2.8%). Moderate effort to run.
Evidence base: the annual asthma review is the process gap between the register and outcomes.
Policy anchor: Core20PLUS5 chronic respiratory disease priority.
Option 2
Older-adult hypertension and lipid review
Across 6,547 hypertension patients (14.4%), 80+ BP control fell 1.5% to 78.9% (England 81.2%, +2.2%). QRISK >=20% lipid therapy grew +0.2% to 62.6% (England 63.6%, +6.2%); 54,421 lipid-modifying items cost £29,387 more than at England's £1.86 unit cost (£2.40). Moderate effort to run.
Evidence base: the hypertension register is the cohort for case-finding, blood-pressure control and AF anticoagulation; its size and growth set the workload those interventions must cover, and a shortfall in control shows up later as emergency admission.
Policy anchor: Core20PLUS5 (hypertension case-finding and optimal management); NHS CVD ambitions to 2029 on detection, treatment to target and statins for high-risk patients (CVDPREVENT).
Option 3
Inclusion-health physical check recall
The PCN holds 54.7% of Runnymede's SMI register (398 patients, 0.9%) and 59.1% of its learning disability register (233 patients, 0.5%; range -26 to +36 vs England 0.6%). SMI changes trailed England in BP (+0.03 pp vs +4.4 pp; 88.6%) and BMI (+0.6 pp vs +5.1 pp; 88.9%). Moderate effort to run.
Evidence base: the SMI register is the cohort for the annual physical health check; the alcohol record is the delivery measure for alcohol screening and brief intervention.
Policy anchor: Mental Health Investment Standard; NHS alcohol care teams and the From Harm to Hope strategy.
Provenance and audit trail
Provenance and audit trail
Figures are the profile's, drawn from Coplug indicator tables: census, deprivation and QOF measures, MHCLG, Rough sleeping snapshot in England: autumn 2025, OHID, Fingertips diabetes by frailty status: HbA1c control (93712, 93713) and OHID, Fingertips falls: emergency admissions, 65+ and 65 to 79 (22401, 22402), accidental-fall deaths (94002). Every recommended action and option is the profile's own; the evidence-base statements that support them — what each register is the cohort for, and the national policy it serves — are quoted from Coplug's indicator catalogue. No recommendation in this report is authored outside the profile and that catalogue. ICB- and provider-level data (page 8) describes the system the PCN sits in and is not read as PCN performance.
| Recommendation | Indicator(s) | Policy anchor | Data level |
|---|---|---|---|
| Register-based inclusion health outreach (p3) | Core20 cohort (IMD quintile 1) | Core20PLUS5 · 10YHP equity test | PCN |
| SMI health check review (p4) | Record of a BP check in the last 12 months for patients on the MH register (denominator incl. PCAs) | MHIS · From Harm to Hope | PCN |
| Older adult hypertension review (p5) | Last BP reading of patients (80+ yrs with hypertension) in the last 12 months is <= 150/90 mmHg (denominator incl. PCAs) | Core20PLUS5 CVD · CVDPREVENT 2029 | PCN |
| Preschool booster recall review (p6) | MMR dose 2 coverage at age 5 | 10YHP sickness to prevention · 95% target | PCN |
| Targeted breast screening recall (p7) | Breast screening coverage: aged 53 to 70 years old | — | PCN |
| Telephony and triage access review (p9) | GPPS easy to contact the practice by phone | 10YHP, hospital to community | Practice |
| Option 1 · Structured respiratory annual review recall (p12) | Asthma register · Patients with Asthma: review in the last 12 months (denominator incl. PCAs) · COPD register | Core20PLUS5 respiratory | PCN & Practice |
| Option 2 · Older-adult hypertension and lipid review (p12) | Hypertension register · Hypertension: QOF prevalence · Last BP reading of patients (80+ yrs with hypertension) in the last 12 months is <= 150/90 mmHg (denominator incl. PCAs) | Core20PLUS5 CVD · CVDPREVENT 2029 | PCN & Practice |
| Option 3 · Inclusion-health physical check recall (p12) | Severe mental illness register · Severe mental illness: QOF prevalence · Learning disability register | MHIS · From Harm to Hope · 75% annual health checks (Network Contract DES) · Oliver McGowan | PCN |
Data sources
Data sources
Every figure in this profile comes from a dataset below, at the level and period stated. Nothing published above PCN level is read as PCN performance.
| Dataset | Level | Period | Used for |
|---|---|---|---|
| Coplug indicator tables: census, deprivation and QOF measures | PCN & Practice | 2023 to 2025, projected to 2030; 2023 to 2024 | Pages 1, 2, 3, 4, 5, 6, 7, 8, 10, 12 |
| MHCLG, Rough sleeping snapshot in England: autumn 2025 | Local authority | Autumn 2025 | Pages 2, 4 |
| OHID, Fingertips diabetes by frailty status: HbA1c control (93712, 93713) | PCN | 2024/25 | Pages 2, 4 |
| OHID, Fingertips falls: emergency admissions, 65+ and 65 to 79 (22401, 22402), accidental-fall deaths (94002) | Local authority | 2024/25; 2022-24 | Pages 2, 4 |
| ONS, Census 2021 TS039: provision of unpaid care (age-standardised) | Local authority | Census 2021 | Pages 2, 4 |
| QOF registers, prevalence and care processes (Coplug indicator tables) | Practice | 2023 to 2025, projected to 2030 | Pages 4, 5, 6, 7, 8, 10 |
| UKHSA, COVER supplementary GP data, childhood immunisation coverage, Q1 2025/26 | PCN & Practice | Q1 2025/26 | Pages 4, 6 |
| UKHSA, Seasonal influenza vaccine uptake in GP patients, 2025 to 2026 | ICB | 2025/26 season to 28 Feb 2026 | Pages 4, 6 |
| NHS England, Cancer Waiting Times: July 2026 monthly time series with revisions | ICB & Provider | Jul 2026 (provisional) | Pages 7, 8 |
| NHS England, Community Services Statistics (CSDS): June 2026 provisional experimental data | ICB & Local authority | Jun 2026 (provisional) | Pages 7, 8 |
| NHS England, Monthly Diagnostics Waiting Times and Activity (DM01): provider by test, July 2026 | Provider | Jul 2026 | Pages 7, 8 |
| National Disease Registration Service, Stage at diagnosis by cancer site in England, 2013 to 2022 | ICB | 2022 | Pages 7, 8 |
| NHS England / Ipsos, GP Patient Survey 2026: practice results (weighted) | Practice | Survey Jan-Apr 2026 | Page 9 |
| NHS England, Quality and Outcomes Framework 2025-26: achievement by practice and domain | Practice | 2025/26 | Page 9 |
| NHS England, Quality and Outcomes Framework 2025-26: personalised care adjustments by practice and domain | Practice | 2025/26 | Page 9 |
| Coplug indicator catalogue — definitions, cohorts, policy anchors | Reference | Current | Evidence-base lines, page 13 |
Methods, data-quality notes and limitations
Methods, data-quality notes and limitations
Methods
Estimated gaps apply benchmark prevalence to the registered population and subtract the recorded register. They size the task; they are not confirmed missed patients.
Percentage points are the difference between two rates; a relative change is that difference as a share of the starting rate. Register changes are relative, over three years.
Forecasts to 2030 extend each indicator's current trajectory with no change in case-finding or service model: a baseline to act against, not a prediction.
Core20 is the most deprived 20% nationally (IMD quintile 1). Practice shares are not additive to the PCN figure. Ethnic minority is 100% minus White. Local-authority averages are unweighted.
